Information Provided By: 
Fly News Breaks for February 9, 2016
PFE
Feb 9, 2016 | 08:07 EDT
BofA/Merrill analyst Colin Bristow added Phizer to the US 1 list and named it a top pick for 2016 and reiterated his Buy rating and $39 price target. The analyst views valuation is compelling, pipeline expectations are low, and the company has significant balance sheet strength. Additionally, Bristow believes merger arbitrage short selling provides some downside protection in the event the deal falls through.
News For PFE From the Last 2 Days
PFE
Apr 22, 2024 | 08:13 EDT
Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
